To assess the efficacy and tolerability of lithium for the treatment of acute mania in children and adolescent diagnosed with bipolar disorder.
the United States have identified manic-like symptoms in clinically referred prepubertal children. 4, 5 These very early onset "bipolar" patients almost always have comorbid externalizing and attentiondeficit hyperactivity disorders (ADHD), as well as an ultra-rapid cycling non-remitting illness course with a high rate of psychotic symptoms-all of which is consistent with a profile that predicts lithium non-response in adults with bipolar disorder. 6, 7 Given that the brain undergoes growth and development at a remarkable pace during childhood and adolescence, along with the atypical phenotype of paediatric mania in prepubertal children, generalizing treatment from the findings in bipolar adults does not seem reasonable or acceptable. Therefore, a cautionary approach in using centrally active medication during the formative years of the nervous system is wise, but at the same time, it is also important to evaluate the potential benefits and adverse effects of an effective treatment such as lithium, and research its use in children that may be suffering from a serious form of the same illness. This is particularly important because recent evidence suggests that lithium may have several benefits including neuroprotective effects, and a delay in the initiation of treatment has been found to be associated with poor outcomes. [8] [9] [10] Therefore, as a joint effort between IGSLi (www.igsli.org) and the ISBD Task Force on Lithium Treatment (www.isbd.org/active-taksforces), the objective of this study was to summarize the available evidence concerning the effectiveness and tolerability of lithium in the treatment of paediatric mania using a systematic review.
| PATIENTS AND ME THODS

| Search strategy
This review was designed and conducted in accordance with PRISMA guidelines. 11 A study protocol was registered in PROSPERO (CRD42017055675) and published in a peer-reviewed journal. 12 Multiple databases were searched including EMBASE, MEDLINE, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov for randomized controlled trials. Search terms such as "bipolar disorder" and "mania," combined with a list of antipsychotics or mood stabilizers and terms such as "child" or "adolescent" were used. Full details of the search strategy, including all the text words and keywords that were used and the list of websites, can be found in the protocol published in PROSPERO.
These searches were supplemented by screening previous relevant reviews, as well as the bibliographies of the included studies. The last search was conducted on August 20, 2017.
| Inclusion and exclusion criteria
| Participants
Studies that comprised male and female participants up to and including 18 years of age with a primary diagnosis of bipolar disorder and experiencing acute mania as part of a manic or mixed episode or rapid-cycling illness, according to standardized diagnostic criteria such as DSM or equivalent, were included in this review. Studies that included samples with serious concomitant medical illnesses, neurological disorder, diagnosed intellectual disability, or brain injury were excluded. 12 Mania had to be confirmed in a face-to-face interview with the child.
| Interventions
Studies were included if they compared lithium with placebo or an alternative active drug that is used in the treatment of acute mania, including atypical and typical antipsychotics and anticonvulsants.
Lithium could be administered by any method at any dose falling within or close to the therapeutic range (0.4-1.2 mmol/l); there was no stringent requirement for a particular lithium dosing strategy, as the therapeutic range in children and adolescents is not known. All interventions could be monotherapy or in combination with other drugs. We included studies which allowed participants to continue on stable medication or to use rescue medication provided these were applied equally across the treatment arms.
| Types of studies
Included studies were randomized controlled trials. We removed the blinding requirement from our original protocol after finding that there were very few studies meeting this criterion and even the "blinded" studies were inconsistent in terms of blind integrity. We reasoned that it would be more informative to include all studies regardless of blinding, and to review the blinding strategy in our risk of bias assessment. However, we remained stringent in our requirement for studies to be truly randomized; hence, any studies reporting a quasi-random design using different, less adequate forms of allocation (ie, alternating) were excluded. No language, publication date, or publication status restrictions were imposed. We included all studies irrespective of outcome. We excluded relapse prevention studies and other maintenance studies, as patients were not acutely manic in these trials.
| Data extraction and quality assessment
Two authors (NH and AW) independently screened all abstracts identified from the search and selected potentially relevant studies. The full text of the selected studies was then screened independently by the same reviewers and data extracted into a pilot-tested excel data abstraction sheet. Any disagreement was resolved through discussion with a third author (SG). Where possible, we extracted intention-to-treat (ITT) data. Risk of bias was assessed using the Cochrane Risk of Bias Tool 13 and discrepancies were discussed amongst four authors (AD, SG, NH, and AW) and resolved through discussion with other members of the review team when necessary (SP and AC). Studies were not excluded based on risk of bias judgements, but are discussed in this review in the context of these potential biases.
Every effort was made to contact study authors for missing information relevant to this review.
Primary outcomes
• Efficacy: Difference in response (as defined by a decrease in score on any validated mania rating scale of ≥50% from baseline) between lithium and comparatively treated patients (placebo or other anti-manic agent) at designated time points.
• Tolerability: Difference in serious adverse events (eg, death, renal failure, diabetes insipidus, clinically significant ECG changes, toxic rash) between lithium and comparatively treated patients.
• Acceptability: Differences in discontinuation rates for any reason between lithium and comparatively treated patients.
Secondary outcomes
• Efficacy: Difference in remission (YMRS 14 score of ≤12 or equivalent) between lithium and comparatively treated patients at designated time points.
• Efficacy: Difference in mean endpoint scores and change in scores of manic symptoms (as measured by the YMRS or equivalent).
• Tolerability: Differences in specific side effects including but not limited to cognitive impairment, diarrhoea, gastric irritation, nausea, haematological abnormalities, hypothyroidism, hyperparathyroidism, polyuria, non-toxic rash, somnolence, lethargy, thirst, tremor, weight gain.
| Analysis
We calculated the relative risk (RR) with corresponding 95% the analysis included three or more studies. However, in the single instance in which meta-analysis was used, there was no evidence of heterogeneity and therefore a fixed effects model was used.
| RE SULTS
| Study selection
The electronic searches, together with screening the bibliographies of relevant records, yielded 516 unique, potentially relevant studies.
On inspection of titles and abstracts, 53 potentially eligible articles were retrieved and the full-text reviewed. We excluded 46 studies that did not meet the eligibility criteria. In total, four independent studies, [16] [17] [18] [19] described in seven published articles, were included in this systematic review ( Figure 1 ). Together these 4 studies examined a total of 176 independent cases of patients randomized and treated with lithium either as a monotherapy or as an adjunct to risperidone.
| Description of included studies
A description of study characteristics can be found in Table 1 . Four of the included reports were independent studies [16] [17] [18] [19] and three were additional analyses from the Treatment of Early Age Mania Study (TEAM). [20] [21] [22] All included trials were conducted in the US and recruited participants from outpatient clinics, except for the TEAM trials where >60% of participants were recruited from media and other sources. One study was an 8-week double-blind randomized trial of lithium compared to placebo, 17 the TEAM study 16 was a single-blind 8-week trial of lithium compared to divalproex sodium and risperidone. The remaining two included studies were non-blind studies: a small 6-week open study of lithium compared to divalproex sodium and carbamazepine 18 and a 26-week open study of lithium or divalproex in combination with risperidone. 19 Three of the included studies were simple two-or three-armed parallel groups studies, [17] [18] [19] while the TEAM study 16 involved two separate randomizations. In the first phase, anti-manic medication-naive participants were randomized to treatment with one of the three study medications, while non-medication naïve participants judged as having a history of non-response or partial response to any one of the investigational medications were eligible for the cross-taper/add-on study arm, described in Walkup et al 2015. 20 If the medication-naive participants from the Geller et al 16 TEAM study showed either no response or partial response at the end of 8 weeks of treatment, they too were eligible to be re-randomized into the cross-taper/add-on study. Data from the Walkup et al 20 study is not included in our analysis because insufficient information was provided to allow separation of the 89 independent cases from the 65 patients who took part initially in the Geller et al study. 16 The two remaining included studies were secondary post hoc analyses of the TEAM trial of anti-manic treatment naïve patients reported by Geller et al 16 One paper focused on moderators and predictors of treatment response, 21 while the other study assessed the efficacy of study medications in reducing depressive and suicidal symptoms. 22 There was considerable heterogeneity in outcome measurement in terms of response and remission definitions across included studies. Furthermore, several studies did not provide sufficient information for us to assess response and remission according to standard definitions as described in our systematic review protocol. 
| Risk of bias assessment
There was evidence of a potential high or unclear risk of bias in at least one of the six categories for each of the included independent F I G U R E 2 Efficacy as a continuous measure (mean endpoint score or mean change in score) on a validated mania rating scale in randomized trials comparing lithium with placebo or with active comparators [Colour figure can be viewed at wileyonlinelibrary.com] studies (Supporting information Table S1 ). One limitation across three of the studies was the lack of blinding of both the research personnel and the participants and their families. In some instances, included studies were rated as either unclear or high risk of bias pertaining to possible selective reporting and attrition biases.
| Assessment of heterogeneity
There was only one instance in which meta-analytic pooling was possible ( Figure 2 ). This pooling used estimates from three studies using a fixed effects model. A SMD was pooled in this part of the analysis (I 2 = 0%).
| Clinical characteristics of study samples
Clinical characteristics of patients in the included studies [16] [17] [18] [19] are shown in Table 2 . A large proportion of the study participants were prepubertal and chronically unwell with an average duration of the acute manic/mixed episode of over 4 years. There was a high proportion of mixed relative to manic episodes and the estimated age of onset of bipolar disorder was very young (around 5 years of age) across all studies reporting this information. Furthermore, there
were high rates of psychiatric comorbidity across all studies with the highest reported in the TEAM study. In particular, in all the included studies, comorbid rates of ADHD were 64% or higher, and in the TEAM study, comorbid ADHD was present in >90% of the sample.
The TEAM study also reported high rates of comorbid behavioural disorders (>85%) including oppositional defiant disorder and disruptive behaviour disorder. Prior exposure to anti-manic medications differed between studies. Only the TEAM study specifically required anti-manic medication-naïve subjects, 16 while the other three studies had different criteria for eligibility and medication taper/washout of prior psychotropic medication.
| Efficacy
Efficacy data from each study are summarized in Supporting information although remission rates according to the authors' own criteria are included in Supporting information As shown in Figure 2 , efficacy defined as a continuous measure of mean change in mania rating scale score from baseline to endpoint (YMRS, KMRS) was estimated. Data from the Findling et al study 17 provides marginal evidence (P = 0.07) that lithium is more effective than placebo (SMD −0.42, 95% CI: −0.88 to 0.04). Data from three studies 16, 18, 19 suggest that lithium has no benefit over divalproex sodium in efficacy (SMD −0.07, 95% CI: −0.31 to 0.18). For this comparison (Figure 2, 1.1.2 ), in accordance with standard practice, 23 we imputed the standard deviation for the Pavuluri study 19 from the Kowatch et al study, 18 as this data was missing. Data from the largest TEAM study 16 provides evidence that risperidone is more effective than lithium in treating acute mania in children (SMD 0.85, 95% CI:
0.54 to 1.15).
| Tolerability
We did not conduct a quantitative analysis of serious adverse events (SAEs) across studies owing to the infrequency and heterogeneity in definitions. The majority of side effects were described across studies as mild to moderate. Findling et al 17 reported five SAEs in those randomized to lithium compared to two SAEs in those randomized to placebo, but none were believed related to the study medication (ie, agitation, psychosis, suicidality). Similarly, in the TEAM study, 16 there was a total of four SAEs with none of these attributed to the treatment (ie, running into the street after an argument with mother about ice cream, homicidal thoughts towards a sibling). The other studies reported no SAEs. 18, 19 Common side effects reported in lithium-treated patients across studies included nausea, vomiting, frequent urination, and excessive thirst. In two studies, there was also evidence of significantly increased thyrotropin levels in lithium-treated patients compared to those treated with placebo or other active comparator. 16, 17 While lithium in comparison to placebo or other active comparator showed no increase in weight, risperidone was associated with significantly increased weight gain and prolactin levels. 16, 19 Specifically, in the Findling et al study, 17 there was no difference in weight gain between the lithium-and placebo-treated groups. In the TEAM trial, 16 weight gain was increased in risperidone-treated patients compared to lithium-treated patients (3.31 kg (1.75) vs 1.42 kg (1.62);
P < 0.001).
In the Pavuluri et al 19 study, both the treatment groups gained weight after adjusting for the expected normal growth over the 24-week study period (ie, lithium + risperidone = 6 ± 3.8 kg; divalproex + risperidone = 6.8 ± 4.2 kg).
| Acceptability
The acceptability of the different interventions defined by dropout rate as a dichotomous measure (ie, risk ratio) can be found in Figure 3 . 16 In the Findling et al study, 17 there was no statistically significant difference in the length of continuing in the study between the treatment groups, with an all cause discontinuation rate for lithium of 30% compared to 25% for placebo. Discontinuation rates were high but comparable across the F I G U R E 3 Acceptability (drop-out rate) as a dichotomous measure (relative risk) in randomized trials comparing lithium with placebo or with active comparators [Colour figure can be viewed at wileyonlinelibrary.com] treatment groups in the Kowatch et al, study 18 and much higher in the lithium + risperidone (65%) group compared to the divalproex + risperidone group (0%) in the study reported on by Pavuluri et al 
| Other studies
Walkup et al 20 provided evidence that risperidone was more effective as a cross-over or add-on medication for children who were originally non-or partial responders to another anti-manic medication. For example, response rates for children switched to risperidone (48%) were significantly higher compared to lithium (13%) and divalproex (17%); while for partial responders, those in whom risperidone was added, had response rates of 53% compared to a response rate of 27% and 0% for those with lithium or divalproex added-on, respectively. Salpekar et al 22 reported that depressive symptoms improved for all the three TEAM study treatment groups in acutely manic/mixed children, but the rate of improvement was significantly greater for those treated with risperidone (61%) as compared to lithium (42%) or divalproex (35%). Vitiello and colleagues
21
examined the effects of clinical variables and study site on outcomes.
They reported that the rate of response differed by study site and that ADHD was a treatment response modifier. Specifically, patients with ADHD had a higher response rate to risperidone compared to lithium (RR 2.1, 95% CI: 1.5 to 3.0; P < 0.0001), but this response difference was not present in patients without comorbid ADHD (RR 1.0, 95% CI: 0.6 to 1.8; P = 1.000).
| D ISCUSS I ON
To our knowledge, this is the first systematic review of the efficacy and tolerability of lithium compared to placebo or other active comparator for treatment of manic or mixed episodes in paediatric bipolar patients. The main finding from this systematic review is the lack of available evidence about the efficacy and tolerability of lithium for acute treatment of classical (ie, narrow phenotype) paediatric mania especially in adolescent patients. The four reviewed studies, which included a total of 176 patients treated with lithium, were heterogeneous and all had methodological limitations that constrained the interpretation of the results. Furthermore, all reviewed studies were conducted in the United States and the patients included were mostly prepubertal children with a very early onset and a "bipolar phenotype" characterized by protracted or chronic mixed episodes with high rates of comorbid ADHD. This presentation differs considerably from that of classical or narrowly defined manic-depressive illness that would be expected to have high response rates to lithium treatment. 6, [24] [25] [26] Keeping in mind the limited number of observations and the clinical characteristics of the patients studied, the findings provide some evidence that lithium may be more efficacious than placebo in the treatment of manic episodes in children. In the single study comparing lithium with placebo, 17 the rate of ADHD and externalizing disorders was lower than in the other included studies-especially compared to the TEAM study. 16 An important clinical question is whether age modifies the effect of lithium. The effect size of lithium vs placebo that we found in our study is not materially different from the results reported in a review about the treatment of mania in adults (SMD −0.40, 95% CI: −0.54 to −0.26). 27 However, the estimate is more precise in the adult population because it is based on larger and more robust evidence (ie, 1 study and 81 patients vs 7 studies and 1366 patients, respectively).
It is also worth noting that in our systematic review risperidone is more efficacious than either lithium or sodium divalproex in the treatment of protracted or chronic manic-like or mixed episodes in very young children with very high rates of comorbid ADHD. Both in the secondary analysis of the TEAM data reported by Vitello et al 21 and in an independent study reported by Masi et al, 28 comorbid ADHD predicted for non-response to lithium treatment of paediatric mania. The rate of ADHD in the children studied is much higher than that reported in US studies of bipolar adults. 29, 30 This finding references the ongoing debate as to whether or not chronic mood dysregulation and explosive temper associated with ADHD and oppositional behaviour in prepubertal children represents a distinct early-onset form of bipolar disorder or some other illness entirely that preferentially responds to risperidone. 31 Tolerability profiles for all agents in the short-term appeared to be generally acceptable with mostly mild to moderate side effects and few SAEs that were all deemed unrelated to the treatment.
However, there was evidence that risperidone alone or in combination is associated with significantly increased weight gain and prolactin levels. Common side effects for lithium treated patients included nausea, excessive thirst and increased urination, which likely reflects high plasma levels related to the dosing regimen used. For example, in the TEAM study, 16 lithium was titrated to a blood level of 0.8 mEq/L in Week 1 and then to 0.9-1.0 mEq/L in Week 2, and adjusted again to 1.1-1.3 mEq/L in Week 4. In the double-blind placebo-controlled trial, 17 the mean daily dose of lithium was seemingly quite high-1483 mg ± 584 at last study visit. Common side effects reported by lithium-treated paediatric patients were similar to those reported in lithium-treated adults, and may have been mitigated by targeting a lower dose and blood level range over a somewhat longer titration period-especially as in all cases subjects were outpatients. 32 A recent pharmacodynamics study supports this view suggesting that in 61 paediatric bipolar I disorder (BDI) patients a mean lithium blood level of 0.71 mEq/L was sufficient to realize a 50% reduction in YMRS scores over a 24-week period.
33
Owing to small numbers of total patients, we did not perform a sensitivity analysis. However, post hoc analyses from the TEAM study provide further information. For example, the companion switch or add-on study reported by Walkup and colleagues 20 provided evidence that risperidone is a more effective cross-over or add-on medication compared to lithium or divalproex for children who were non or partial responders to a prior anti-manic medication. Salpekar et al 22 reported that depressive symptoms improved for all the three TEAM study treatment groups in children in a protracted manic/mixed episode, but the rate of improvement was statistically significantly greater for those treated with risperidone. Vitiello and colleagues 21 reported that the rate of response differed by study site and that ADHD was a treatment response modifier. The implication being that the superiority of risperidone over lithium may be limited to paediatric patients in a protracted mixed/manic episode comorbid with ADHD.
The findings from this systematic review outline a striking paucity of studies evaluating the efficacy and tolerability of lithium treatment of mania in adolescent bipolar patients. This is particularly problematic given that both prospective studies of high-risk children and retrospective studies of bipolar adults provide convergent evidence that index manic episodes most typically occur in late adolescence and early adulthood. 34, 35 Adolescence marks a critical period of accelerated brain development that occurs within a complex and evolving hormonal and psychosocial context. 36 Therefore, evidence to inform clinicians about the effectiveness and tolerability of lithium treatment for adolescent-onset acute mania seems of critical importance.
Evidence from open studies supports the notion that lithium may be an effective and generally tolerated treatment for acute mania in adolescents. 37, 38 The largest of these, conducted by Kafantaris and colleagues, 38 reported response rates (55%) and effect sizes (1.48)
for lithium after 4 weeks of treatment comparable to the findings from the randomized controlled studies reviewed here (ie, Kowatch et al 18 reported an effect size of 1.06 for lithium using change from baseline to exit in the YMRS scores). There is also evidence suggesting that adjunctive antipsychotic medication added to a mood stabilizer may improve response rates in acutely manic adolescents with or without psychosis-at least in the short term. [39] [40] [41] The use of antipsychotic medication, alone or in combination, is associated with a higher risk of weight gain and metabolic syndrome, while lithium is associated with renal and thyroid effects. Therefore, the benefit to risk ratio of exposure to medication needs to be considered, and until more is known, it seems prudent to recommend limited exposure, aiming for monotherapy when possible, and use of the lowest effective dose for the shortest duration.
While beyond the scope of this review, there is insufficient evidence to inform us about the appropriate length of anti-manic treatment in paediatric bipolar patients, and about selection of patients who might benefit from treatment continuation or how to estimate the appropriate length for such maintenance treatment. Evidence from the adult literature suggests that using the patient profile-including information about the premorbid developmental history and clinical course, family history of illness and treatment response in affected relatives, and quality of remission data-helps to predict which mood stabilizer used for continuation and prophylaxis will be effective for individual patients. 25, 42, 43 There is also preliminary evidence to support that predictors of lithium response hold true in adolescent patients earlier in the course of bipolar disorder. 44, 45 Furthermore, a recent prospective study reported that 4 weeks of lithium treatment for acute adolescent manic or mixed episode was associated with normalization of white matter microstructure in a region of interest for both bipolar disorder and emotional regulation, providing preliminary evidence of a neural predictor of lithium response. 46 Mounting evidence supports that lithium has profound neuroprotective properties-seemingly protecting and perhaps even reversing structural changes caused by mood disorders. 47 Functionally, lithium is thought to protect against suicide possibly by limiting impulsive behaviour and ideation, and diminishing irritability and rumination. But whether these effects in adults hold in children and adolescents is not known. 48 The molecular, cellular, neural circuitry, and cognitive effects of lithium that underpin its clinical properties all point to changes that are likely to be affected irrespective of age.
In other words, it is quite likely that lithium has similar neuroprotective effects in youth and possibly children-though the psychological and clinical manifestation of this will necessarily be quite different.
For example, the inhibition of GSK3β by lithium is a key to its pharmacology resulting in the modulation of the HPA axis and neurotransmission, and the reduction in inflammation and oxidative stress.
Akin to other agents, lithium also affects clock gene expression and encourages neuroplasticity. These are all processes that are active in childhood and thus susceptible to lithium's effects. 8 Therefore, there are potential advantages to lithium treatment and its efficacy requires much more study-especially since plasma levels can be readily monitored and lithium's water binding propensity means that it interferes little with metabolic functions and plasma protein binding.
Our understanding of the developmental trajectory and aetiopathogenesis of bipolar disorder suggests that it first takes hold in adolescence and possibly younger, 49 and that early disruptions accumulate gradually culminating in significant dysfunction. Indicators of these changes have been observed using DTI as changes in the myelination of nerves, using fMRI as altered network connectivity, and when examined post-mortem as the structural integrity of brain tissue. 8 The need for a medication, such as lithium, is therefore present-but whether its use can be justified given the paucity of evidence to date is a matter for debate.
| Limitations
In this project, we employed a rigorous methodology to synthesize evidence and collect in a transparent and replicable way, all available data (including unpublished information). 50 However, the main limitation in our systematic review relates to the lack of available literature to inform the question of efficacy and tolerability in paediatric patients. While this study followed strict PRISMA guidelines, after identifying the small number of studies that met our inclusion criteria, we decided to deviate from our original protocol 12 on the inclusion criteria pertaining to the blinding of studies. However, both independent screeners systematically screened all identified studies from our initial search a second time to ensure that non-blinded studies were included in a systematic way. The studies included in this review mostly involved very young children with an atypical bipolar phenotype and chronic course associated with high rates of comorbid ADHD and externalizing disorders, thus generalizability to the treatment of classical (ie, narrowly defined) mania is very limited.
This systematic review focused on acute treatment of mania and did not address maintenance or prophylactic treatment.
| CON CLUS IONS
The results from this systematic review provide some evidence that lithium maybe a potentially efficacious and generally well-tolerated treatment for some forms of paediatric mania-especially when ADHD is not comorbid. However, evidence is limited in that less than 180 patients treated with lithium were included in studies reviewed. Furthermore, most paediatric patients studied suffered from a form of illness inconsistent with classical bipolar disorder and had a clinical profile that predicts for lithium non-response.
Evidence from the available literature resonates with clinical practice-essentially that for the treatment of severe mania the addition of short-term antipsychotic treatment likely reduces the time to and improves the overall rate of acute treatment response.
However, it should be mentioned that the approach to acute treatment of mania is very different to the approach needed for effective and well-tolerated maintenance and prophylactic treatment aiming to protect against recurrence of bipolar disorder episodes (of either polarity). 7, 42, 43 Finally, there is extremely limited data in paediatric patients to inform us as to how long effective and tolerated acute medication should be continued, how efficacious and safe prophylac- 
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